TrialThe Lancet. Oncology2019

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Paul G Corn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.